ARTBIO and PharmaLogic inks supply agreement for Lead-212 based Therapeutic Candidate for treatment of prostate cancer
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York